Fig. 8
Luminal B human breast tumors exhibit a SIRT3/MnSOD-K68-Ac signature. a, b MCF7 and MCF7-HTR cells (5.0 × 106) were implanted into both hind limbs of nude mice and tumor volumes were measured for 6 weeks. a Error bars represent ± 1 SEM. b Representative images of the tumors from MCF7-HTR (left panel) and MCF7 cells (right panel) at 6 weeks. c MCF7-HTR doxycycline-inducible MnSODK68R cells were implanted into hind limbs of nude mice and tumor volumes were monitored for 4 weeks. Error bars represent ± 1 SEM. d Luminal breast cancer sample TMA stained with anti-MnSOD-K68-Ac or anti-SIRT3 antibodies. e, f Quantified TMA consisting of luminal A (n = 37) and luminal B (n = 38) samples immunostained for e MnSOD-K68-Ac; and f SIRT3. The shaded boxes represent the interquartile range; whiskers represent the 10th–90th percentile range. Experiments were done in triplicate. *p < 0.05. A t-test was used to compare data between the two groups. g Schematic of the dichotomous role for MnSOD in normal cells (i.e., protection, blue) versus tumor promoter and/or and Tam resistance (red)
